Beraprost-314d Added-on to Tyvaso® (BEAT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.
Also called NCT01908699
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 273 participants
- Sponsor
- Lung Biotechnology PBC
- Registry
-
NCT01908699
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Israel
- Registry status
- Completed
Technical summary
Registry record NCT01908699. Randomized; triple masking; primary purpose treatment. Start 2013-05-31 (actual); primary completion 2019-02-19 (actual). Results posted on 2020-02-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Beraprost-314d Added-on to Tyvaso® (BEAT)
- Acronym
- BEAT
- Condition
- Pulmonary Arterial Hypertension
- Intervention (Drug)
- Beraprost Sodium 314d Modified Release Tablets
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lung Biotechnology PBC
Record details
- Record id
cardio:ct-nct01908699- Content hash
08b0e3f41eb33bef31fa159f971efdf6033cd9df1ec1f89ac09a968822c74f55